On September 29, KEYMED BIO-B rose 8.48% in regular trading, trading at HKD 79.0/share, with turnover of HKD 128 million. The stock rallied alongside the broader innovative drug sector, which saw broad-based gains driven by two major catalysts.

On the news front, AstraZeneca announced a USD 2 billion strategic equity investment in Summit Therapeutics, the overseas partner of Akeso (康方生物). The deal centers on ivosdenib, a first-in-class PD-1/VEGF bispecific antibody previously licensed by Akeso to Summit for up to USD 5 billion. AstraZeneca will lead clinical development of ivosdenib in combination with its ADC pipeline across multiple tumor types. The investment is widely viewed as a top-tier pharma endorsement of ivosdenib's global commercial potential. Concurrently, Akeso disclosed updated HARMONi-2 overall survival data at the World Lung Cancer Conference, showing median OS of 30.8 months versus 22.6 months for pembrolizumab (HR=0.73).

Akeso surged over 13% on the day, generating strong sector sentiment spillover. KEYMED BIO-B, which collaborates with AstraZeneca on CMG901 and recently reported H1 revenue of RMB 617 million (+24% YoY) with a net profit swing to RMB 1.218 billion, benefited from both sector momentum and its own improving fundamentals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)